Onesource Specialty Pharma Limited has informed the Exchange about Other Restructuring
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On September 26, 2025, the board of OneSource Specialty Pharma approved a composite scheme merging four group entities into itself: Steriscience Specialties (SSPL) into Brooks Steriscience (BSL), then BSL and Steriscience Pte (Singapore) into OneSource, along with its wholly-owned Strides Pharma Services (no share issuance). Shareholders of BSL will get 137 OneSource shares for every 10 BSL shares, and Steriscience SG shareholders will get 53 OneSource shares for every 100 ordinary shares. The scheme also includes a financial restructuring to set off OneSource's accumulated losses against its Securities Premium Account, cleaning up the balance sheet. Rationale: consolidate the group's CDMO (contract development and manufacturing) operations, add a European Union manufacturing site, and build a multi-modality CDMO platform. Key numbers: OneSource standalone turnover ₹12,995.89 million and net worth ₹59,108.37 million (FY25). Approvals needed: shareholders, creditors, SEBI, NCLT, Singapore Court.
Existing public shareholders will see their stake diluted from 70.23% to 63.83% as ~2.61 crore new shares are issued to promoters of merging entities, pushing promoter holding from 29.77% to 36.17%. The deal could be value-accretive in the long run through operational synergies and a cleaner balance sheet, but it needs to clear NCLT, SEBI, and shareholder votes (with a public shareholder majority requirement) before becoming effective.